Ready for risk sharing? Performance-based agreements as a catalyst of innovative pharmacotherapy

• Authors: Weronika Wojturska

Abstracts

EN

Since health authorities and pharmaceutical companies are risk-averse in the reimbursement process, risk-sharing agreements (RSAs) can be seen as a happy medium for ensuring that the inherent financial and clinical risks of implementing a new innovative treatment are minimized. Although a properly applied RSA lies in the interest of patients, payers and manufacturers, the initial analysis shows that implementation of performance-based RSAs (PBRSAs), tied to measurable health outcomes, faces numerous obstacles in Poland. The article seeks to propose solutions, taking into account the characteristics of PBRSAs in Italy and the United Kingdom. The analysis is in line with the current trend of gradual remodelling of the Polish system towards value-based healthcare. The methods employed include a broad conceptual and exploratory analysis of Polish and foreign literature and legal acts, data acquired from national health data repositories, materials published by pharmaceutical consortia, financial institutions and public authorities engaged in managing the medicine market in Europe.

Keywords

EN

risk-sharing agreement; RSA; performance-based RSA; PBRSA; reimbursement; pharmacotherapy

• Publisher: Fundacja Instytut Nauki o Polityce
• Journal: Polish Journal of Political Science
• Year: 2023
• Volume: 9
• Issue: 3
• Pages: 30-49

Dates

published

2023

Contributors

author

Weronika Wojturska

• Uniwersytet Warszawski

References

• Ustawa z dnia 12 maja 2011 r. o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych, Dz. U. 2011 Nr 122 poz. 696 z późn. zm., [Act of 12 May 2011 on the reimbursement of medicines, foodstuffs for special nutritional purposes and medical devices, Journal of Laws 2011, No. 122, item 696 as amended].
• Adamski J., Godman B., Ofierska-Sujkowska G., Osińska B., Herholz H., Wendykowska K., Laius O., Jan S., Sermet C., Zara C., Kalaba M., Gustafsson R., Garuolienè K., Haycox A., Garattini S., Gustafsson L.L., Correspondence Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers, “BMC Health Services Research”, 2010, Vol. 10, pp. 1–16, DOI: 10.1186/1472-6963-10-153.
• Aggarwal R., Risk-sharing Agreements: Country Experiences and Challenges, 2014, pp. 1–8, https://www.insead.edu/sites/default/files/assets/dept/centres/hmi/docs/rsa-experiencesandchallenges-insead-hmi.pdf, (access 01.08.2023).
• Barros P.P., Pharmaceutical policies in European countries, “AdvHealth Econ Health Serv Res.”, 2010, Vol. 22, pp. 3–27, DOI: 10.1108/s0731-2199(2010)0000022004.
• Boggild M., Palace J., Barton P., Ben-Shlomo Y., Bregenzer T., Dobson Ch., Gray R., Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator, “BMJ”, 2009, Vol. 339, pp. 1–9, DOI: 10.1136/bmj.b4677.
• Breckenridge A., Walley T., Risk sharing and payment by results, “Clin Pharmacol Ther.”, 2008, Vol. 83 (5), pp. 666–667, DOI: 10.1038/clpt.2008.15.
• Buch C., Schildmann J., Zerth J., Risk-sharing schemes to finance expensive pharmaceuticals: Interdisciplinary analyses, in: Defining the Value of Medical Interventions: Normative and Empirical Challenges, eds. J. Schildmann, C. Buch, J. Zerth, W. Kohlhammer GmbH 2021, https://www.ncbi.nlm.nih.gov/books/NBK585090/#ch07sec1_2, (access 05.06.2023).
• Carapinha J.L., Setting the stage for risk-sharing agreements: international experiences and outcomes-based reimbursement, “South African Family Practice”, 2008, Vol. 50 (4), pp. 62–65, DOI: 10.1080/20786204.2008.10873741.
• Carlson J.J., Gries K.S., Yeung K., Sullivan S.D., Garrison Jr L.P., Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers, “Appl Health Econ Health Policy”, 2014, Vol. 12 (3), pp. 231–238, DOI: 10.1007/s40258-014-0093-x.
• Carlson J.J., Sullivan S.D., Garrison L.P., Neumann P.J., Veenstra D.L., Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers, “Health Policy”, 2010, Vol. 96 (3), pp. 179–190, DOI: 10.1016/j.healthpol.2010.02.005.
• Chirico G., Managed entry agreements: €195m saved by the Italian healthcare system in 2022, https://remapconsulting.com/managed-entry-agreements/managed-entry-agreements-e195m-saved-by-the-italian-healthcare-system-in-2022/, (access 18.08.2023).
• Cook J.P., Vernon J.A., Manning R., Pharmaceutical risk-sharing agreements, “Pharmacoeconomics”, 2008, Vol. 26 (7), pp. 551–556, DOI: 10.2165/00019053-200826070-00002.
• Coulton L., Annemans L., Carter R., Baltazar Herrera M., Thabrany H., Lim J., Lee K.K.C., Chen W., Chaiyakunapruk N., Chern H-D., Lee T-J., Nakamura H., Yen-Huei Tarn T., Keskinaslan A., Outcomes-based risk-sharing schemes: is there a potential role in the Asia-Pacific markets?, “Health Outcomes Research in Medicine”, 2012, Vol. 3 (4), pp. 205–219, DOI: 10.1016/j.ehrm.2012.07.002.
• Garattini L., Curto A., van de Vooren K., Italian risk-sharing agreements on drugs: are they worthwhile?, “Eur J Health Econ.”, 2015, Vol. 16 (1), pp. 1–3, DOI: 10.1007/s10198-014-0585-5.
• Garrison L., Towse A., Briggs A., de Pouvourville G., Grueger J., Mohr P.E., Severens J.L.H., Siviero P., Sleeper M., Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation. Report of the ISPOR good practices for performance-based risk-sharing arrangements task force, “Value in Health”, 2013, Vol. 16 (5), pp. 703–719, DOI: 10.1016/j.jval.2013.04.011.
• Garrison L.P., Carlson J.J., Bajaj P.S., Towse A., Neumann P.J., Sullivan S.D., Westrich K., Dubois R.W., Private sector risk-sharing agreements in the United States: trends, barriers, and prospects, “Am J Manag Care”, 2015, Vol. 21 (9), pp. 632–640.
• Gonçalves F.R., Santos S., Silva C., Sousa G., Risk-sharing agreements, present and future, “Ecancermedicalscience”, 2018, Vol. 12, pp. 1–11, DOI: 10.3332/ecancer.2018.823.
• Izmirlieva M., Challenges with risk sharing in Eastern Europe raised at ISPOR Europe meeting, 2019, https://www.pharmaceutical-technology.com/pricing-and-market-access/challenges-with-risk-sharing-in-eastern-europe-raised-at-ispor-html/, (access 23.06.2023).
• Kanavos P., Ferrario A., Tafuri G., Siviero P., Managing risk and uncertainty in health technology introduction: the role of managed entry agreements, “Global Policy”, 2017, Vol. 8 (2), pp. 84–92, DOI: 10.1111/1758-5899.12386.
• Kannarkat J.T., Good Ch.B., Kelly E., Parekh N., Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts, “Journal of Managed Care & Specialty Pharmacy”, 2020, Vol. 26 (1), pp. 63–66, DOI: 10.18553/jmcp.2020.26.1.63.
• Kawalec P., Malinowski K.P., Relating health technology assessment recommendations and reimbursement decisions in Poland in years 2012–2014, a retrospective analysis, “Health Policy”, 2016, Vol. 120 (11), pp. 1240–1248, DOI: 10.1016/j.healthpol.2016.09.021.
• Kim A.E., Choi D.H., Chang J., Kim S.H., Performance‐Based Risk‐Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?, “Clinical Drug Investigation”, 2020, Vol. 40 (12), pp. 1107–1113, DOI: 10.1007/s40261-020-00972-w.
• Klemp M., Frønsdal K.B., Facey K., HTAi Policy Forum, What principles should govern the use of managed entry agreements?, “Int J Technol Assess Health Care”, 2011, Vol. 27 (1), pp. 77–83, DOI:10.1017/S0266462310001297.
• Klimczak M., Decyzje o refundacji leków są transparentne i podlegają ścisłej kontroli, 2018, https://www.gov.pl/web/zdrowie/decyzje-o-refundacji-lekow-sa-transparentne-i-podlegaja-scislej-kontroli, (access 30.07.2023).
• Malinowski K., Kawalec P., Trąbka W., Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012–2014, “Health Policy”, 2016, Vol. 120 (11), pp. 1249–1255, DOI: 10.1016/j.healthpol.2016.09.016.
• McCabe C., Bergmann L., Bosanquet N., Ellis M., Enzmann H., von Euler M., Jönsson B., Kallen K-J., Newling D., Nüssler V., Paschen B., de Wilde R., Wilking N., Teale C., Zwierzina H., Biotherapy Development Association, Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective, “Annals of Oncology”, 2009, Vol. 20 (3), pp. 403–412, DOI: 10.1093/annonc/mdn603.
• McCabe C., Stafinski T., Edlin R., Menon D., Banff AED Summit, Access with evidence development schemes - a framework for description and evaluation, “Pharmacoeconomics”, 2010, Vol. 28 (2), pp. 143–152, DOI: 10.2165/11530850-000000000-00000.
• Morel T., Arickx F., Befrits G., Siviero P., van der Meijden C., Xoxi E., Simoens S., Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries,“ Orphanet Journal of Rare Diseases”, 2013, Vol. 8, pp. 1–15, DOI: 10.1186/1750-1172-8-198.
• Pagliarulo N., Pushing 'value,' Harvard Pilgrim tests outcomes deals, 2018, https://www.biopharmadive.com/news/harvard-pilgrim-astrazeneca-symbicort-value-contract/521659/, (access 07.07.2023).
• Palace J., Duddy M., Bregenzer T., Lawton M., Zhu F., Boggild M., Piske B., Robertson N.P., Oger J., Tremlett H., Tilling K., Ben-Shlomo Y., Dobson Ch., Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator, “The Lancet Neurology”, 2015, Vol. 14 (5), pp. 497–505.
• Pomorski M.K., Matusewicz W., Lipińska A., Types of Risk-Sharing Schemes Proposed in Reimbursement Application Received by AOTMIT in 2015, “Value in Health”, 2016, Vol. 19, https://www.valueinhealthjournal.com/article/S1098-3015(16)32258-6/fulltext, (access 22.06.2023).
• Richardson B., Bentley S., MacKinnon P., Dillon A., Mohanna N., Forming Value-Based Agreements in the UK, 2022, https://www.carnallfarrar.com/wp-content/uploads/2022/05/TL-Value-Based-Agreements_v924.pdf, (access 08.09.2023).
• Stafinski T., McCabe Ch.J., Menon D., Funding the unfundable - mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems, “Pharmacoeconomics”, 2010, Vol. 28 (2), pp. 113–142, DOI: 10.2165/11530820-000000000-00000.
• Towse A., Garrison L., Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk sharing agreements for innovative medical products, “Pharmacoeconomics”, 2010, Vol. 28 (2), pp. 93–102, DOI: 10.2165/11314080-000000000-00000.
• Watt A., Risk-sharing agreements are growing at a rate of 24%, 2023, https://www.pharmaceutical-technology.com/pricing-and-market-access/risk-sharing-agreements/?cf-view, (access 03.08.2023).
• Wenzl M., Chapman S., Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward, “OECD Health Working Papers”, 2019, No. 115, OECD Publishing, DOI: 10.1787/6e5e4c0f-en.
• Wojturska W., In search of a remedy for public-private partnership (PPP) hospital infrastructure projects in Poland – a comparative law study Part I: Poland, “Medicine and Law Journal of World Association for Medical Law”, 2023, Vol. 42, No. 2, pp. 451–480.
• Zhang H., Huang T., Yan T., A quantitative analysis of risk-sharing agreements with patient support programs for improving medication adherence, “Health Care Manag Sci.”, 2022, Vol 25 (2), pp. 253–274, DOI: 10.1007/s10729-021-09587-9.
• AIFA, L’uso dei farmaci in Italia. Rapporto Nazionale Anno 2022, https://www.aifa.gov.it/documents/20142/1967301/Rapporto-OsMed-2022.pdf, (access 17.08.2023).
• AIFA, Registri farmaci sottoposti a monitoraggio, https://www.aifa.gov.it/web/guest/registri-farmaci-sottoposti-a-monitoraggio, (access 06.08.2023).
• Biuletyn Informacji Publicznej Agencji Oceny Technologii Medycznych i Taryfikacji, https://bipold.aotm.gov.pl/index.php/rada-przejrzystosci/5084-wykaz-obowiazujacych-opinii, (access 15.06.2023).
• Bogusławski S., Libura M., Obarska I., Mikułowska M., Grzybała P., Złożone instrumenty dzielenia ryzyka – możliwości rozwoju w Polsce, 2018, https://www.infarma.pl/assets/files/PEX_Raport_Zloz_instrumenty_dzielenia_ryzyka%E2%80%93mozliwosci_rozwoju_w_Polsce_20190225.pdf, (access 23.06.2023).
• Cancer-drug refund scheme backed, http://news.bbc.co.uk/2/hi/6713503.stm, (access 08.09.2023).
• Health Technology Assessment (HTA), Wytyczne oceny technologii medycznych, https://www.aotm.gov.pl/media/2020/07/20160913_Wytyczne_AOTMiT-1.pdf, (access 15.06.2023).
• Medicine shortages and availability issues, https://www.ema.europa.eu/en/human-regulatory/post-authorisation/availability-medicines, (access 01.06.2023).
• NICE, Patient Access Schemes Liaison Unit, https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit#list-of-arrangements, (access 03.09.2023).
• Pacjenci.Pro, Proces refundacyjny w Polsce, https://pacjencipro.hta.pl/upload/surveys/364433/files/PacjenciPro_Proces_refundacyjny.pdf, (access 03.08.2023).
• Pharmaceutical Group of the European Union, Medicine Shortages Survey 2022, https://www.pgeu.eu/wp-content/uploads/2023/01/Medicine-Shortages-PGEU-Survey-2022-Results-1.pdf, (access 01.06.2023).
• Value-Based Contracting In The US, https://www.huronconsultinggroup.com/insights/value-based-contracting-in-us, (access 25.06.2023).

Identifiers

DOI

10.58183/pjps.03042023

Biblioteka Nauki

23050980